Prior authorization & UM · Lab / specialty PA + transparency
Careviso
Careviso builds seeQer for prior authorization, eligibility, and financial transparency, with a long lab and specialty-provider footprint. It is not a payer clinical UM determination console.
Strong fit
- Labs and specialty groups buried in prior authorizations under the medical benefit
- Patient access teams that also want insurance checks, cost estimates, and prior authorization submission in one workflow
- Buyers who track days to authorization and enrollment across a large network of ordering providers
Weak fit
- Health plans building their own system to make utilization management decisions
- Clinics with almost no prior authorizations that only need a fax cover sheet
- Buyers who will not change how staff handle problem cases after submissions are automated
Bottom line
Careviso is worth using for labs and specialty providers whose prior authorizations stall on portal searches and incomplete submissions. It suits access teams with a clear owner and clean order feeds. Health plans that need software to make authorization decisions should look at Agadia or Xsolis.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Careviso builds seeQer, a patient access platform. It automates prior authorizations, benefit checks, and cost estimates for labs, specialty providers, and ordering networks.
Careviso says hundreds of thousands of providers are enrolled and its authorization volume is growing. It works for providers and labs, not for health plans making utilization management decisions.
Customers get faster authorizations and fewer abandoned orders when seeQer handles insurance checks, cost estimates, and authorization routing together.
Getting there needs a named access owner and clean order data. Prices are quoted for each customer.
Among prior authorization tools we review, Careviso scores close to Agadia overall, though the two solve different problems. It scores above Silna and SamaCare.
Silna or SamaCare fit specialty clinics that need help getting patients ready for care. Infinitus fits when phone follow-up with payers is the bottleneck, and Hindsait fits health plans that need AI to read clinical records during review.
The score reflects strong results for lab and specialty authorizations. It is less suited to health plans that need a full policy engine.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Xsolis | 7.8 | 7.3 |
| Infinitus | 7.7 | 7.4 |
| Humata Health | 7.7 | 7.4 |
| Agadia | 7.6 | 7.2 |
| Careviso | 7.6 | 7.3 |
| Silna Health | 7.3 | 7.1 |
| Itiliti Health | 7.3 | 7.1 |
| Banjo Health | 7.2 | 7.0 |
| Hindsait | 7.0 | 6.7 |
| Rhyme | 6.5 | 6.3 |
Pricing
| Item | Detail |
|---|---|
| Model | A platform for prior authorization, insurance checks, and cost estimates, with prices quoted for each customer. |
| What usually drives cost | Authorization volume, the size of your provider network, which seeQer modules you use (prior authorization, cost estimates, pharmacy benefit), and the support level. |
| What to ask before you buy | The full cost at your monthly volume of authorizations and estimates, with clear terms for enrollment and problem cases. |
| Published pricing | Careviso does not publish prices. Expect pricing based on volume. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Careviso to function | |
| A named prior authorization or access lead who can change how submissions work | Software with no owner goes unused. |
| Current numbers for authorization turnaround, denials, and abandoned orders | You cannot show value without a starting number. |
| A written list of data coming from the EHR, ordering, or practice management systems | Missing data sends staff back to retyping into payer portals. |
| A staffing plan for problem cases after launch | Problem cases no one owns turn into delayed care. |
| A list of the payers and services with the most prior authorizations | A generic setup misses where you really get stuck. |
| What will maximize your value | |
| Track the typical days to authorization every week for 90 days | Counting logins does not show results. |
| Start with one specialty or one lab | A small real win is worth more than a broad launch with nothing behind it. |
| Drop duplicate tracking spreadsheets after one month running both | Entering everything twice doubles the cost. |
| Review stuck cases in a regular short meeting | Cases that quietly sit hide problems. |
| Send clinical and finance leaders a monthly access summary | Delays no one reports surprise everyone later. |
| Deal-breakers | |
| No one will own prior authorization problem cases. | |
| You will not do the connection or enrollment work it needs. | |
| You expect a prior authorization tool to replace your EHR. | |
| Leaders will not measure how long authorizations take. | |
| Your compliance team blocks the data sharing that submissions need. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Plan and measure the starting point | 2-4 weeks. Agree on measures, list payers, and list data sources. |
| 2 | Set up | 4-10 weeks. Build rules, templates, and connections, and test real cases. |
| 3 | Pilot | 2-6 weeks. Run one specialty or site and write down how to handle problem cases. |
| 4 | Expand | 1-3 months. Add payers and sites, and stop using side trackers. |
Leadership
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.